147 related articles for article (PubMed ID: 10374907)
1. Janus kinases and their role in growth and disease.
Aringer M; Cheng A; Nelson JW; Chen M; Sudarshan C; Zhou YJ; O'Shea JJ
Life Sci; 1999; 64(24):2173-86. PubMed ID: 10374907
[TBL] [Abstract][Full Text] [Related]
2. A new protein containing an SH2 domain that inhibits JAK kinases.
Endo TA; Masuhara M; Yokouchi M; Suzuki R; Sakamoto H; Mitsui K; Matsumoto A; Tanimura S; Ohtsubo M; Misawa H; Miyazaki T; Leonor N; Taniguchi T; Fujita T; Kanakura Y; Komiya S; Yoshimura A
Nature; 1997 Jun; 387(6636):921-4. PubMed ID: 9202126
[TBL] [Abstract][Full Text] [Related]
3. The role of Jak3 in lymphoid development, activation, and signaling.
Thomis DC; Berg LJ
Curr Opin Immunol; 1997 Aug; 9(4):541-7. PubMed ID: 9287175
[TBL] [Abstract][Full Text] [Related]
4. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
5. Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.
Cacalano NA; Migone TS; Bazan F; Hanson EP; Chen M; Candotti F; O'Shea JJ; Johnston JA
EMBO J; 1999 Mar; 18(6):1549-58. PubMed ID: 10075926
[TBL] [Abstract][Full Text] [Related]
6. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone receptor interaction with Jak proteins differs between tissues.
Hellgren G; Albertsson-Wikland K; Billig H; Carlsson LM; Carlsson B
J Interferon Cytokine Res; 2001 Feb; 21(2):75-83. PubMed ID: 11244571
[TBL] [Abstract][Full Text] [Related]
8. The Janus kinases (Jaks).
Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.
Avalos BR; Parker JM; Ware DA; Hunter MG; Sibert KA; Druker BJ
Exp Hematol; 1997 Feb; 25(2):160-8. PubMed ID: 9015216
[TBL] [Abstract][Full Text] [Related]
11. Human lung myofibroblasts as effectors of the inflammatory process: the common receptor gamma chain is induced by Th2 cytokines, and CD40 ligand is induced by lipopolysaccharide, thrombin and TNF-alpha.
Doucet C; Giron-Michel J; Canonica GW; Azzarone B
Eur J Immunol; 2002 Sep; 32(9):2437-49. PubMed ID: 12207328
[TBL] [Abstract][Full Text] [Related]
12. The janus kinase inhibitor, Jab/SOCS-1, is an interferon-gamma inducible gene and determines the sensitivity to interferons.
Sakamoto H; Kinjyo I; Yoshimura A
Leuk Lymphoma; 2000 Jun; 38(1-2):49-58. PubMed ID: 10811447
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
14. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
Pesu M; Candotti F; Husa M; Hofmann SR; Notarangelo LD; O'Shea JJ
Immunol Rev; 2005 Feb; 203():127-42. PubMed ID: 15661026
[TBL] [Abstract][Full Text] [Related]
15. JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells.
Rane SG; Reddy EP
Oncogene; 1994 Aug; 9(8):2415-23. PubMed ID: 7518579
[TBL] [Abstract][Full Text] [Related]
16. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
17. Jak3 and the pathogenesis of severe combined immunodeficiency.
O'Shea JJ; Husa M; Li D; Hofmann SR; Watford W; Roberts JL; Buckley RH; Changelian P; Candotti F
Mol Immunol; 2004 Jul; 41(6-7):727-37. PubMed ID: 15220007
[TBL] [Abstract][Full Text] [Related]
18. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Cetkovic-Cvrlje M; Uckun FM
Arch Immunol Ther Exp (Warsz); 2004; 52(2):69-82. PubMed ID: 15179321
[TBL] [Abstract][Full Text] [Related]
19. Defective lymphoid development in mice lacking Jak3.
Nosaka T; van Deursen JM; Tripp RA; Thierfelder WE; Witthuhn BA; McMickle AP; Doherty PC; Grosveld GC; Ihle JN
Science; 1995 Nov; 270(5237):800-2. PubMed ID: 7481769
[TBL] [Abstract][Full Text] [Related]
20. Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling.
Narazaki M; Fujimoto M; Matsumoto T; Morita Y; Saito H; Kajita T; Yoshizaki K; Naka T; Kishimoto T
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13130-4. PubMed ID: 9789053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
